FXI 📈 iShares China Large-Cap - Overview

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US4642871846 • China Region

FXI: Chinese, Stocks, Companies, Hong Kong

The iShares China Large-Cap ETF, traded on the NYSE ARCA under the ticker symbol FXI, is designed to track the performance of the largest and most liquid Chinese companies listed on the Stock Exchange of Hong Kong, making it accessible to international investors. By investing at least 80% of its assets in the component securities of its underlying index, or in investments that have similar economic characteristics, the fund aims to replicate the performance of the Chinese large-cap market. This underlying index is specifically designed to measure the performance of the largest companies in the Chinese equity market that are available to international investors, providing a benchmark for the fund's performance.

As a non-diversified fund, the iShares China Large-Cap ETF may have a higher concentration of assets in a smaller number of securities, which can result in higher volatility compared to a diversified fund. However, this concentration can also allow the fund to more closely track the performance of the largest Chinese companies, potentially providing investors with exposure to the growth and development of the Chinese economy. With its domicile in the United States and an ISIN of US4642871846, the fund is classified as an exchange-traded fund (ETF) in the China Region category, offering investors a convenient and liquid way to gain exposure to the Chinese market.

The fund's investment strategy is designed to provide investors with a cost-effective and efficient way to gain exposure to the Chinese large-cap market, while also providing the benefits of trading on a major US exchange. As part of the iShares family of ETFs, the fund is supported by a robust infrastructure and a well-established brand, with more information available on the company's website at http://www.ishares.com. By tracking the performance of the largest Chinese companies listed on the Stock Exchange of Hong Kong, the iShares China Large-Cap ETF offers investors a unique opportunity to participate in the growth and development of the Chinese economy, while also providing the benefits of liquidity and transparency associated with trading on a major US exchange.

Additional Sources for FXI ETF

FXI ETF Overview

Market Cap in USD 7,302m
Category China Region
TER 0.74%
IPO / Inception 2004-10-05

FXI ETF Ratings

Growth 5y -23.6%
Fundamental -
Dividend 16.0%
Rel. Strength Industry 29.6
Analysts -
Fair Price Momentum 29.40 USD
Fair Price DCF -

FXI Dividends

Dividend Yield 12m 0.27%
Yield on Cost 5y 0.22%
Annual Growth 5y -8.63%
Payout Consistency 93.8%

FXI Growth Ratios

Growth Correlation 3m -65.2%
Growth Correlation 12m 85.8%
Growth Correlation 5y -77.2%
CAGR 5y -4.37%
CAGR/Mean DD 5y -0.13
Sharpe Ratio 12m 0.96
Alpha 17.75
Beta 0.60
Volatility 29.32%
Current Volume 20218.1k
Average Volume 20d 42645.2k
What is the price of FXI stocks?
As of December 27, 2024, the stock is trading at USD 31.09 with a total of 20,218,100 shares traded.
Over the past week, the price has changed by +3.46%, over one month by +6.25%, over three months by +6.75% and over the past year by +36.33%.
Is iShares China Large-Cap a good stock to buy?
Neither. Based on ValueRay Analyses, iShares China Large-Cap is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -23.56 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FXI as of December 2024 is 29.40. This means that FXI is currently overvalued and has a potential downside of -5.44%.
Is FXI a buy, sell or hold?
iShares China Large-Cap has no consensus analysts rating.
What are the forecast for FXI stock price target?
According to ValueRays Forecast Model, FXI iShares China Large-Cap will be worth about 32.3 in December 2025. The stock is currently trading at 31.09. This means that the stock has a potential upside of +3.83%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 32.3 3.8%